On November 17, 2022 Vivesto reported that Interim report for the period January 1, 2022 – September 30, 2022 (Press release, Vivesto, NOV 17, 2022, View Source [SID1234624190])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SIGNIFICANT EVENTS DURING THE THIRD QUARTER
In July Christer Nordstedt was appointed acting CEO.
In July Vivesto announced that the company has decided to wind down its activities in Russia following the Russian invasion of Ukraine, ongoing hostilities and international sanctions. The wind down of Vivesto’s activities in Russia means that a write down of SEK 44.6 million is carried out during the third quarter of 2022, equal to the net book value of the capitalized development costs for Paclical after amortization as of June 30, 2022.
In August, Vivesto’s and Elevar’s partner Inceptua began the commercial launch of Apealea in Germany.

SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD
In November Vivesto announced that the acting CEO Christer Nordstedt had resigned from his position in order to assume a new role outside of the company. Christer Nordstedt will remain as senior advisor to Vivesto on a consultancy basis within R&D.

THIRD QUARTER: JULY 1, 2022 – SEPTEMBER 30, 2022
Consolidated net sales amounted to TSEK 1,015 (11,920)
Operating profit/loss was TSEK 71,318 (-29,572)
Write-down of development costs attributable to Russia TSEK -44,624 (0)
Operating profit/loss adjusted for write-down of development costs attributable to Russia
TSEK -26,694 (-29,572), a decrease of SEK 2,878

Net profit/loss after tax amounted to TSEK -71,682 (-30,987)
Earnings per share amounted to SEK -0.14 (-0.07)
THE PERIOD: JANUARY 1, 2022 – SEPTEMBER 30, 2022
Consolidated net sales amounted to TSEK 1,015 (16,553)
Operating profit/loss was TSEK -133,970 (-126,579)
Write-down of development costs attributable to Russia TSEK -44,624 (0)
Operating profit/loss adjusted for write-down of development costs attributable to Russia TSEK -89,346 (-126 579), a decrease of SEK 37,233
Net profit/loss after tax amounted to TSEK -136,653 (-129,873)
Earnings per share amounted to SEK -0.28 (-0.29)
Short-term investments, cash and cash equivalents amounted to TSEK 164,241 (149,677)
Equity/assets ratio was 95% (80%)

Invitation to presentation of Vivesto’s Q3 report
Vivesto will hold a conference call and an online presentation of the Q3 report on November 17, 2022, at 10.00 am CET. The call will be hosted by Acting CEO Christer Nordstedt and Acting CFO Robert Maiorana. The presentation will be in English and followed by a question-and-answer session. The conference call will be broadcast live on the web via the link:
View Source